Predominance of ERG-negative high-grade prostate cancers in African American men.

PubWeight™: 0.85‹?›

🔗 View Article (PMID 25279185)

Published in Mol Clin Oncol on August 07, 2014

Authors

James Farrell1, Denise Young2, Yongmei Chen2, Jennifer Cullen2, Inger L Rosner1, Jacob Kagan3, Sudhir Srivastava3, David G McLEOD1, Isabell A Sesterhenn4, Shiv Srivastava2, Gyorgy Petrovics2

Author Affiliations

1: Department of Surgery, Center for Prostate Disease Research, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA ; Department of Urology, Walter Reed National Military Medical Center, Bethesda, MD 20889, USA.
2: Department of Surgery, Center for Prostate Disease Research, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA.
3: Cancer Biomarkers Research Group, Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
4: Department of Genitourinary Pathology, Joint Pathology Center, Silver Spring, MD 20910-1290, USA.

Articles cited by this

Cancer statistics, 2013. CA Cancer J Clin (2013) 84.72

Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science (2005) 39.06

Antibody-based detection of ERG rearrangement-positive prostate cancer. Neoplasia (2010) 3.66

Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome. Oncogene (2005) 3.13

Common gene rearrangements in prostate cancer. J Clin Oncol (2011) 2.89

ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratification. Prostate Cancer Prostatic Dis (2010) 2.24

The mutational landscape of prostate cancer. Eur Urol (2013) 2.14

TMPRSS2-ERG gene fusion prevalence and class are significantly different in prostate cancer of Caucasian, African-American and Japanese patients. Prostate (2010) 2.05

Interplay of race, socioeconomic status, and treatment on survival of patients with prostate cancer. Urology (2009) 1.44

Delineation of TMPRSS2-ERG splice variants in prostate cancer. Clin Cancer Res (2008) 1.35

Epidemiology, pathology, and genetics of prostate cancer among African Americans compared with other ethnicities. Methods Mol Biol (2009) 1.25

Clinical potential of the ERG oncoprotein in prostate cancer. Nat Rev Urol (2012) 1.17

Differences in frequency of ERG oncoprotein expression between index tumors of Caucasian and African American patients with prostate cancer. Urology (2012) 1.16

ERG protein expression and genomic rearrangement status in primary and metastatic prostate cancer--a comparative study of two monoclonal antibodies. Prostate Cancer Prostatic Dis (2012) 1.16

Biological determinants of health disparities in prostate cancer. Curr Opin Oncol (2013) 1.12

Evaluation of the ETS-related gene mRNA in urine for the detection of prostate cancer. Clin Cancer Res (2010) 1.09

Genetic and molecular differences in prostate carcinogenesis between African American and Caucasian American men. Int J Mol Sci (2013) 1.03

Contemporary grading for prostate cancer: implications for patient care. Eur Urol (2012) 1.03

Prostate cancer in men 70 years old or older, indolent or aggressive: clinicopathological analysis and outcomes. J Urol (2010) 0.91